Gastrodin reduced iNOS and COX-2 expression in LPS-stimulated BV-2 cells. The iNOS mRNA response at 30 µM lacked a significance marker; 40 and 60 µM were marked significant. These are expression endpoints rather than enzyme-activity measurements. [1]
In zinc-challenged C6 astroglial cells, 24 h gastrodin co-treatment improved the MTT viability signal at 50 and 100 µM. The 250 µM group lacked a significance marker, so a monotonic concentration-response relationship is not supported. [3]
Gastrodin reduced p16, p21 and SA β-gal senescence markers in peroxide-challenged HUVECs. The experiment concerns an induced cellular senescence model and does not establish prevention of vascular aging in animals or humans. [2]
Inflammatory enzyme expression in activated BV-2 microglia
Cell-based study · Immortalized mouse BV-2 microglial cells [1]
Gastrodin reduced inflammatory enzyme expression relative to LPS alone; iNOS mRNA at 30 µM lacked a significance marker. Protein evidence was representative immunofluorescence, not enzyme activity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 30, 40 and 60 µM
- Exposure duration
- 1 h pretreatment, then 4 h stimulation
- Method
- Pretreatment before LPS (1 µg/mL); untreated and LPS-only controls.
- Co-treatment
- LPS is the inflammatory challenge, not a therapeutic combination.
- Reported limits
- Gastrodin vehicle, purity and lot analytical identity are not specified in the examined Methods. No gastrodin-only treatment group in the five-group design.
Methods and source locations
Compound reported in the paper: Gastrodin; Compound label in the paper: gastrodin
Findings apply to the named research material and specified model; no analytical or performance validation of an Adooq lot.
Figures 1–3; Methods: Cells and treatments, Double-immunofluorescence labeling assay, RT-PCR analysis, Statistical analysis
iNOS mRNA normalized to β-actin and representative protein staining: RT-PCR densitometry; representative double-immunofluorescence images. — Figure 2A–B and caption
COX-2 mRNA normalized to β-actin and representative protein staining: RT-PCR densitometry; representative double-immunofluorescence images. — Figure 3A–B and caption
Early phosphorylation responses in BV-2 microglia
Cell-based study · Immortalized mouse BV-2 microglial cells [1]
Gastrodin attenuated stimulus-induced phosphorylation of IκB-α, CREB and MAPKs. These are cellular associations rather than direct binding or purified-enzyme inhibition.
Literature-Reported Treatment Conditions
- Treatment concentration
- 30, 40 and 60 µM
- Exposure duration
- 1 h pretreatment, then 30 min stimulation
- Method
- Pretreatment before LPS (1 µg/mL); untreated and LPS-only controls.
- Co-treatment
- LPS inflammatory challenge.
- Reported limits
- Vehicle and purity unspecified; no gastrodin-only group.
Methods and source locations
Compound reported in the paper: Gastrodin; Compound label in the paper: gastrodin
Findings apply to the named research material and specified model; no analytical or performance validation of an Adooq lot.
Figure 7A–E and caption; Methods: Cells and treatments, Western blot analysis, Statistical analysis; Discussion final paragraphs
Phosphorylated IκB-α, CREB, ERK1/2, JNK and p38 MAPK: Phospho-IκB-α and phospho-CREB normalized to β-actin; phospho-MAPKs normalized to corresponding total MAPK. — Figure 7A–E and caption; Results: Gastrodin decreases LPS-induced phosphorylation of MAPKs family
Gastrodin co-treatment in zinc-challenged C6 cells
Cell-based study · Rat C6 astroglial cell line [3]
Co-treatment improved the MTT signal at 50 and 100 µM gastrodin. At 250 µM, Figure 3A lacks a significance marker; benefit was not monotonic across the tested range.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50, 100 or 250 µM
- Exposure duration
- 24 h co-treatment
- Method
- Co-treatment with 50 µM zinc sulfate; untreated and zinc-only controls.
- Co-treatment
- Zinc sulfate is the injury challenge.
- Reported limits
- The cell-assay gastrodin vehicle is not specified separately; the DMSO statement occurs in the animal Drug injection subsection.
Methods and source locations
Compound reported in the paper: Gastrodin; Compound label in the paper: GAS
Findings apply to the named research material and specified model; no analytical or performance validation of an Adooq lot.
Figure 3A and caption; Methods: C6 astroglial cell culture and Zn2+ treatment, Cell viability assays, Statistical analysis; Results: Suppression of Zn2+-induced C6 astroglial death by GAS
MTT viability relative to untreated cells: MTT assay; absorbance at 550 nm. n=4 is retained as reported; biological independence is not specified. — Figure 3A and corresponding Results paragraph
Senescence markers and HO-1 inhibitor sensitivity in HUVECs
Cell-based study · Human umbilical vein endothelial cells (HUVECs; ATCC), hydrogen peroxide senescence model [2]
Gastrodin lowered senescence markers and increased nuclear Nrf2 and HO-1. SnPPIX attenuated the marker reductions, supporting HO-1 involvement without establishing direct target engagement or genetic necessity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 or 100 µM; inhibitor comparison used 100 µM
- Exposure duration
- 6 h gastrodin pretreatment; 24 h follow-up after oxidative challenge. Results §3.2 describes a 2 h H2O2 exposure.
- Method
- 100 µM H2O2 model; SnPPIX 20 µM for 2 h before gastrodin in inhibitor experiments.
- Co-treatment
- Separate HO-1 inhibitor control: SnPPIX, not a combined therapeutic efficacy claim.
- Reported limits
- Vehicle unspecified. General §2.1 and §3.2 differ in wording around the H2O2 exposure/follow-up; washout timing is not resolved. No SnPPIX-only senescence arm in Figure 5.
Methods and source locations
Compound reported in the paper: Gastrodin; Compound label in the paper: GAS
Findings apply to the named research material and specified model; no analytical or performance validation of an Adooq lot.
Figures 2B, 3A–E, 5A–I; Methods §§2.1–2.3, 2.6–2.7; Results §§3.2–3.3, 3.5; Discussion
p16/p21 protein, SA β-gal-positive cells, nuclear Nrf2 and HO-1 protein: Immunoblot densitometry (GAPDH; nuclear Nrf2 normalized to Histone H3 in Figure 5C) and SA β-gal staining. Methods §2.7: mean ± SD from at least three independent experiments. — Figures 3A–E and 5A–I; Results §§3.3, 3.5
Gastrodin-only viability control: CCK-8 viability assay; this control does not establish long-term safety. — Figure 2B; Results §3.2; Methods §§2.1–2.2